Population pharmacokinetics and dose rationale for aciclovir in term and pre‐term neonates with herpes
Open Access
- 22 May 2024
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (3) , e1193
Abstract
Aciclovir is considered the first‐line treatment against Herpes simplex virus (HSV) infections in new‐borns and infants. As renal excretion is the major route of elimination, in renally‐impaired patients, aciclovir doses are adjusted according to the degree of impairment. However, limited attention has been given to the implications of immature renal function or dysfunction due to the viral disease itself. The aim of this investigation was to characterize the pharmacokinetics of aciclovir taking into account maturation and disease processes in the neonatal population. Pharmacokinetic data obtained from 2 previously published clinical trials (n = 28) were analyzed using a nonlinear mixed effects modeling approach. Post‐menstrual age (PMA) and creatinine clearance (CLCR) were assessed as descriptors of maturation and renal function. Simulation scenarios were also implemented to illustrate the use of pharmacokinetic data to extrapolate efficacy from adults. Aciclovir pharmacokinetics was described by a one‐compartment model with first‐order elimination. Body weight and diagnosis (systemic infection) were statistically significant covariates on the volume of distribution, whereas body weight, CLCR and PMA had a significant effect on clearance. Median clearance varied from 0.2 to 1.0 L/h in subjects with PMA CR), suggesting different dosing requirement for pre‐term neonates.Keywords
This publication has 50 references indexed in Scilit:
- Quantitation of viral load in neonatal herpes simplex virus infection and comparison between type 1 and type 2Journal of Medical Virology, 2002
- Multiple Interactions of Cimetidine and Probenecid with Valaciclovir and Its Metabolite AcyclovirAntimicrobial Agents and Chemotherapy, 2002
- Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus InfectionsPediatrics, 2001
- A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus InfectionNew England Journal of Medicine, 1991
- A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: Noninvasive assessment of body composition and growthThe Journal of Pediatrics, 1986
- Overview of acyclovir pharmacokinetic disposition in adults and childrenThe American Journal of Medicine, 1982
- Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humansAntimicrobial Agents and Chemotherapy, 1982
- Disposition of intravenous radioactive acyclovirClinical Pharmacology & Therapeutics, 1981
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- Estimation of human body surface area from height and weight.1970